Imodium A-D

Overview

loperamide

antidiarrheal

1. CYP2C8 substrate
2. CYP3A4 substrate
3. P-gp substrate
4. alters gallbladder contraction/motility
5. decreases gastrointestinal motility
6. prolongs QT interval (conditional)

Contraindicated

• pimozide
Imodium A-D (loperamide)

+

pimozide

1 interaction

Contraindicated

loperamide + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation, paralytic ileus (additive effects)

• potassium chloride
Imodium A-D (loperamide)

+

potassium chloride

1 interaction

Contraindicated

loperamide + potassium chloride

contraindicated w/ solid potassium formulations; consider alternative, incl. liquid potassium formulations: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium citrate
Imodium A-D (loperamide)

+

potassium citrate

1 interaction

Contraindicated

loperamide + potassium citrate

contraindicated w/ solid potassium formulations; consider alternative, incl. liquid potassium formulations: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• thioridazine
Imodium A-D (loperamide)

+

thioridazine

1 interaction

Contraindicated

loperamide + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation, paralytic ileus (additive effects)

• ziprasidone
Imodium A-D (loperamide)

+

ziprasidone

1 interaction

Contraindicated

loperamide + ziprasidone

contraindicated if loperamide dose >16mg/day; otherwise, use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Imodium A-D (loperamide)

+

adagrasib

1 interaction

Avoid/Use Alternative

loperamide + adagrasib

use alternative or monitor ECG, esp. if loperamide dose >16mg/day or if also combined w/ CYP2C8 inhibitor: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• amiodarone
Imodium A-D (loperamide)

+

amiodarone

1 interaction

Avoid/Use Alternative

loperamide + amiodarone

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anagrelide
Imodium A-D (loperamide)

+

anagrelide

1 interaction

Avoid/Use Alternative

loperamide + anagrelide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Imodium A-D (loperamide)

+

apalutamide

1 interaction

Avoid/Use Alternative

loperamide + apalutamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Imodium A-D (loperamide)

+

apomorphine

1 interaction

Avoid/Use Alternative

loperamide + apomorphine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Imodium A-D (loperamide)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

loperamide + arsenic trioxide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Imodium A-D (loperamide)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

loperamide + artemether/ lumefantrine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Imodium A-D (loperamide)

+

asenapine

1 interaction

Avoid/Use Alternative

loperamide + asenapine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• azithromycin
Imodium A-D (loperamide)

+

azithromycin

1 interaction

Avoid/Use Alternative

loperamide + azithromycin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Imodium A-D (loperamide)

+

bedaquiline

1 interaction

Avoid/Use Alternative

loperamide + bedaquiline

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cabozantinib
Imodium A-D (loperamide)

+

cabozantinib

1 interaction

Avoid/Use Alternative

loperamide + cabozantinib

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ceritinib
Imodium A-D (loperamide)

+

ceritinib

1 interaction

Avoid/Use Alternative

loperamide + ceritinib

use alternative or monitor ECG, electrolytes, esp. if also combined w/ CYP2C8, P-gp inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• chloroquine
Imodium A-D (loperamide)

+

chloroquine

1 interaction

Avoid/Use Alternative

loperamide + chloroquine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cisapride
Imodium A-D (loperamide)

+

cisapride

1 interaction

Avoid/Use Alternative

loperamide + cisapride

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• citalopram
Imodium A-D (loperamide)

+

citalopram

1 interaction

Avoid/Use Alternative

loperamide + citalopram

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clarithromycin
Imodium A-D (loperamide)

+

clarithromycin

1 interaction

Avoid/Use Alternative

loperamide + clarithromycin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• clofazimine
Imodium A-D (loperamide)

+

clofazimine

1 interaction

Avoid/Use Alternative

loperamide + clofazimine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Imodium A-D (loperamide)

+

clozapine

1 interaction

Avoid/Use Alternative

loperamide + clozapine

use alternative: combo may incr. risk of severe constipation, paralytic ileus (incl. life-threatening), other anticholinergic adverse effects (additive effects)

• crizotinib
Imodium A-D (loperamide)

+

crizotinib

1 interaction

Avoid/Use Alternative

loperamide + crizotinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• degarelix
Imodium A-D (loperamide)

+

degarelix

1 interaction

Avoid/Use Alternative

loperamide + degarelix

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Imodium A-D (loperamide)

+

desflurane

1 interaction

Avoid/Use Alternative

loperamide + desflurane

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Imodium A-D (loperamide)

+

desipramine

1 interaction

Avoid/Use Alternative

loperamide + desipramine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus, other adverse effects (additive effects)

• dexmedetomidine
Imodium A-D (loperamide)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

loperamide + dexmedetomidine

use alternative or monitor HR, ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Imodium A-D (loperamide)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

loperamide + dexmedetomidine injection

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• disopyramide
Imodium A-D (loperamide)

+

disopyramide

1 interaction

Avoid/Use Alternative

loperamide + disopyramide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus, other adverse effects (additive effects)

• dofetilide
Imodium A-D (loperamide)

+

dofetilide

1 interaction

Avoid/Use Alternative

loperamide + dofetilide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Imodium A-D (loperamide)

+

domperidone

1 interaction

Avoid/Use Alternative

loperamide + domperidone

use alternative or monitor ECG, HR, electrolytes, especially if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. domperidone efficacy (additive effects; antagonistic effects)

• donepezil
Imodium A-D (loperamide)

+

donepezil

1 interaction

Avoid/Use Alternative

loperamide + donepezil

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Imodium A-D (loperamide)

+

dronedarone

1 interaction

Avoid/Use Alternative

loperamide + dronedarone

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• droperidol
Imodium A-D (loperamide)

+

droperidol

1 interaction

Avoid/Use Alternative

loperamide + droperidol

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eluxadoline
Imodium A-D (loperamide)

+

eluxadoline

1 interaction

Avoid/Use Alternative

loperamide + eluxadoline

avoid combo if chronic loperamide use; D/C loperamide if constipation occurs: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• encorafenib
Imodium A-D (loperamide)

+

encorafenib

1 interaction

Avoid/Use Alternative

loperamide + encorafenib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ephedra
Imodium A-D (loperamide)

+

ephedra

1 interaction

Avoid/Use Alternative

loperamide + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Imodium A-D (loperamide)

+

epirubicin

1 interaction

Avoid/Use Alternative

loperamide + epirubicin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Imodium A-D (loperamide)

+

eribulin

1 interaction

Avoid/Use Alternative

loperamide + eribulin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Imodium A-D (loperamide)

+

erythromycin

1 interaction

Avoid/Use Alternative

loperamide + erythromycin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs when erythromycin used for GI promotility (additive effects; antagonistic effects)

• fexinidazole
Imodium A-D (loperamide)

+

fexinidazole

1 interaction

Avoid/Use Alternative

loperamide + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after loperamide D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Imodium A-D (loperamide)

+

flecainide

1 interaction

Avoid/Use Alternative

loperamide + flecainide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Imodium A-D (loperamide)

+

fluorouracil

1 interaction

Avoid/Use Alternative

loperamide + fluorouracil

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Imodium A-D (loperamide)

+

gilteritinib

1 interaction

Avoid/Use Alternative

loperamide + gilteritinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Imodium A-D (loperamide)

+

glasdegib

1 interaction

Avoid/Use Alternative

loperamide + glasdegib

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Imodium A-D (loperamide)

+

goserelin

1 interaction

Avoid/Use Alternative

loperamide + goserelin

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• haloperidol
Imodium A-D (loperamide)

+

haloperidol

1 interaction

Avoid/Use Alternative

loperamide + haloperidol

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus, other adverse effects (additive effects)

• histrelin
Imodium A-D (loperamide)

+

histrelin

1 interaction

Avoid/Use Alternative

loperamide + histrelin

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• hydroxychloroquine
Imodium A-D (loperamide)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

loperamide + hydroxychloroquine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyzine
Imodium A-D (loperamide)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

loperamide + hydroxyzine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus (additive effects)

• ibutilide
Imodium A-D (loperamide)

+

ibutilide

1 interaction

Avoid/Use Alternative

loperamide + ibutilide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• inotuzumab ozogamicin
Imodium A-D (loperamide)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

loperamide + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Imodium A-D (loperamide)

+

isoflurane

1 interaction

Avoid/Use Alternative

loperamide + isoflurane

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ivosidenib
Imodium A-D (loperamide)

+

ivosidenib

1 interaction

Avoid/Use Alternative

loperamide + ivosidenib

use alternative or monitor ECG, electrolytes esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lefamulin
Imodium A-D (loperamide)

+

lefamulin

1 interaction

Avoid/Use Alternative

loperamide + lefamulin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Imodium A-D (loperamide)

+

leuprolide

1 interaction

Avoid/Use Alternative

loperamide + leuprolide

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Imodium A-D (loperamide)

+

levofloxacin

1 interaction

Avoid/Use Alternative

loperamide + levofloxacin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Imodium A-D (loperamide)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

loperamide + levoketoconazole

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• lofexidine
Imodium A-D (loperamide)

+

lofexidine

1 interaction

Avoid/Use Alternative

loperamide + lofexidine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Imodium A-D (loperamide)

+

lonafarnib

1 interaction

Avoid/Use Alternative

loperamide + lonafarnib

use alternative or monitor HR, ECG, electrolytes, especially if also combined w/ CYP2C8 inhibitor or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• macimorelin
Imodium A-D (loperamide)

+

macimorelin

1 interaction

Avoid/Use Alternative

loperamide + macimorelin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• methadone
Imodium A-D (loperamide)

+

methadone

1 interaction

Avoid/Use Alternative

loperamide + methadone

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• mobocertinib
Imodium A-D (loperamide)

+

mobocertinib

1 interaction

Avoid/Use Alternative

loperamide + mobocertinib

use alternative or monitor ECG, electrolytes, especially if loperamide dose >16 mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• moxifloxacin
Imodium A-D (loperamide)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

loperamide + moxifloxacin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nilotinib
Imodium A-D (loperamide)

+

nilotinib

1 interaction

Avoid/Use Alternative

loperamide + nilotinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oliceridine
Imodium A-D (loperamide)

+

oliceridine

1 interaction

Avoid/Use Alternative

loperamide + oliceridine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• ondansetron
Imodium A-D (loperamide)

+

ondansetron

1 interaction

Avoid/Use Alternative

loperamide + ondansetron

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Imodium A-D (loperamide)

+

osimertinib

1 interaction

Avoid/Use Alternative

loperamide + osimertinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Imodium A-D (loperamide)

+

pacritinib

1 interaction

Avoid/Use Alternative

loperamide + pacritinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paliperidone
Imodium A-D (loperamide)

+

paliperidone

1 interaction

Avoid/Use Alternative

loperamide + paliperidone

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Imodium A-D (loperamide)

+

palonosetron

1 interaction

Avoid/Use Alternative

loperamide + palonosetron

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Imodium A-D (loperamide)

+

pasireotide

1 interaction

Avoid/Use Alternative

loperamide + pasireotide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentamidine
Imodium A-D (loperamide)

+

pentamidine

1 interaction

Avoid/Use Alternative

loperamide + pentamidine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pramlintide
Imodium A-D (loperamide)

+

pramlintide

1 interaction

Avoid/Use Alternative

loperamide + pramlintide

consider alternative: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• procainamide
Imodium A-D (loperamide)

+

procainamide

1 interaction

Avoid/Use Alternative

loperamide + procainamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Imodium A-D (loperamide)

+

propafenone

1 interaction

Avoid/Use Alternative

loperamide + propafenone

use alternative or monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16 mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• quinidine (antiarrhythmic)
Imodium A-D (loperamide)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

loperamide + quinidine (antiarrhythmic)

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Imodium A-D (loperamide)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

loperamide + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Imodium A-D (loperamide)

+

quinine

1 interaction

Avoid/Use Alternative

loperamide + quinine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Imodium A-D (loperamide)

+

quizartinib

1 interaction

Avoid/Use Alternative

loperamide + quizartinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• revefenacin inhaled
Imodium A-D (loperamide)

+

revefenacin inhaled

1 interaction

Avoid/Use Alternative

loperamide + revefenacin inhaled

consider alternative: combo may incr. risk of anticholinergic adverse effects (additive effects)

• revumenib
Imodium A-D (loperamide)

+

revumenib

1 interaction

Avoid/Use Alternative

loperamide + revumenib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Imodium A-D (loperamide)

+

ribociclib

1 interaction

Avoid/Use Alternative

loperamide + ribociclib

use alternative or monitor ECG, electrolytes, especially if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• romidepsin
Imodium A-D (loperamide)

+

romidepsin

1 interaction

Avoid/Use Alternative

loperamide + romidepsin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Imodium A-D (loperamide)

+

rucaparib

1 interaction

Avoid/Use Alternative

loperamide + rucaparib

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Imodium A-D (loperamide)

+

selpercatinib

1 interaction

Avoid/Use Alternative

loperamide + selpercatinib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sevoflurane
Imodium A-D (loperamide)

+

sevoflurane

1 interaction

Avoid/Use Alternative

loperamide + sevoflurane

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Imodium A-D (loperamide)

+

sotalol

1 interaction

Avoid/Use Alternative

loperamide + sotalol

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telavancin
Imodium A-D (loperamide)

+

telavancin

1 interaction

Avoid/Use Alternative

loperamide + telavancin

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tetrabenazine
Imodium A-D (loperamide)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

loperamide + tetrabenazine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ticagrelor
Imodium A-D (loperamide)

+

ticagrelor

1 interaction

Avoid/Use Alternative

loperamide + ticagrelor

consider alternative parenteral antiplatelet agent for acute tx of ACS; otherwise, caution advised: combo may decr. ticagrelor and active metabolite levels, efficacy (absorption of ticagrelor possibly affected by delayed gastric emptying)

• toremifene
Imodium A-D (loperamide)

+

toremifene

1 interaction

Avoid/Use Alternative

loperamide + toremifene

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Imodium A-D (loperamide)

+

tramadol

1 interaction

Avoid/Use Alternative

loperamide + tramadol

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe constipation, paralytic ileus (additive effects)

• triclabendazole
Imodium A-D (loperamide)

+

triclabendazole

1 interaction

Avoid/Use Alternative

loperamide + triclabendazole

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Imodium A-D (loperamide)

+

trifluridine

1 interaction

Avoid/Use Alternative

loperamide + trifluridine

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Imodium A-D (loperamide)

+

triptorelin

1 interaction

Avoid/Use Alternative

loperamide + triptorelin

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• vandetanib
Imodium A-D (loperamide)

+

vandetanib

1 interaction

Avoid/Use Alternative

loperamide + vandetanib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Imodium A-D (loperamide)

+

vemurafenib

1 interaction

Avoid/Use Alternative

loperamide + vemurafenib

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• atazanavir
Imodium A-D (loperamide)

+

atazanavir

1 interaction

Monitor/Modify Tx

loperamide + atazanavir

monitor ECG, esp. if also combined w/ P-gp inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• belumosudil
Imodium A-D (loperamide)

+

belumosudil

1 interaction

Monitor/Modify Tx

loperamide + belumosudil

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• cannabidiol
Imodium A-D (loperamide)

+

cannabidiol

1 interaction

Monitor/Modify Tx

loperamide + cannabidiol

monitor ECG, esp. if also combined w/ CYP3A4 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. possibly inhibited, gut P-gp-mediated transport inhibited)

• chloramphenicol
Imodium A-D (loperamide)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

loperamide + chloramphenicol

monitor ECG, esp. if also combined w/ CYP2C8, P-gp inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• cimetidine
Imodium A-D (loperamide)

+

cimetidine

1 interaction

Monitor/Modify Tx

loperamide + cimetidine

monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• clomipramine
Imodium A-D (loperamide)

+

clomipramine

1 interaction

Monitor/Modify Tx

loperamide + clomipramine

consider decr. dose of one or both drugs: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• cobicistat
Imodium A-D (loperamide)

+

cobicistat

1 interaction

Monitor/Modify Tx

loperamide + cobicistat

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• cyclosporine
Imodium A-D (loperamide)

+

cyclosporine

1 interaction

Monitor/Modify Tx

loperamide + cyclosporine

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• gemfibrozil
Imodium A-D (loperamide)

+

gemfibrozil

1 interaction

Monitor/Modify Tx

loperamide + gemfibrozil

monitor ECG, esp. if also combined w/ CYP3A4, P-gp inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• glecaprevir
Imodium A-D (loperamide)

+

glecaprevir

1 interaction

Monitor/Modify Tx

loperamide + glecaprevir

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• hyoscyamine
Imodium A-D (loperamide)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

loperamide + hyoscyamine

separate admin. by 1h: combo may decr. hyoscyamine levels, efficacy; may incr. risk of severe constipation, paralytic ileus (mechanism unknown; additive effects)

• idelalisib
Imodium A-D (loperamide)

+

idelalisib

1 interaction

Monitor/Modify Tx

loperamide + idelalisib

monitor ECG, esp. if also combined w/ CYP2C8, P-gp inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• itraconazole
Imodium A-D (loperamide)

+

itraconazole

1 interaction

Monitor/Modify Tx

loperamide + itraconazole

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• ketoconazole
Imodium A-D (loperamide)

+

ketoconazole

1 interaction

Monitor/Modify Tx

loperamide + ketoconazole

monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• lopinavir/ritonavir
Imodium A-D (loperamide)

+

lopinavir/ ritonavir

1 interaction

Monitor/Modify Tx

loperamide + lopinavir/ ritonavir

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• mifepristone
Imodium A-D (loperamide)

+

mifepristone

1 interaction

Monitor/Modify Tx

loperamide + mifepristone

monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• nefazodone
Imodium A-D (loperamide)

+

nefazodone

1 interaction

Monitor/Modify Tx

loperamide + nefazodone

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• nelfinavir
Imodium A-D (loperamide)

+

nelfinavir

1 interaction

Monitor/Modify Tx

loperamide + nelfinavir

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• panobinostat
Imodium A-D (loperamide)

+

panobinostat

1 interaction

Monitor/Modify Tx

loperamide + panobinostat

monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pibrentasvir
Imodium A-D (loperamide)

+

pibrentasvir

1 interaction

Monitor/Modify Tx

loperamide + pibrentasvir

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• posaconazole
Imodium A-D (loperamide)

+

posaconazole

1 interaction

Monitor/Modify Tx

loperamide + posaconazole

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• ritonavir
Imodium A-D (loperamide)

+

ritonavir

1 interaction

Monitor/Modify Tx

loperamide + ritonavir

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• sincalide
Imodium A-D (loperamide)

+

sincalide

1 interaction

Monitor/Modify Tx

loperamide + sincalide

if sincalide gallbladder contraction stimulation use, consider D/C loperamide prior to sincalide admin.: combo may alter sincalide efficacy, interfere w/ test results (gallbladder motility/contractility altered)

• tucatinib
Imodium A-D (loperamide)

+

tucatinib

1 interaction

Monitor/Modify Tx

loperamide + tucatinib

monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• verapamil
Imodium A-D (loperamide)

+

verapamil

1 interaction

Monitor/Modify Tx

loperamide + verapamil

monitor ECG, esp. if also combined w/ CYP2C8 inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• vimseltinib
Imodium A-D (loperamide)

+

vimseltinib

1 interaction

Monitor/Modify Tx

loperamide + vimseltinib

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day; give vimseltinib at least 4h before loperamide: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• voriconazole
Imodium A-D (loperamide)

+

voriconazole

1 interaction

Monitor/Modify Tx

loperamide + voriconazole

monitor ECG, esp. if also combined w/ CYP2C8, P-gp inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• voxilaprevir
Imodium A-D (loperamide)

+

voxilaprevir

1 interaction

Monitor/Modify Tx

loperamide + voxilaprevir

monitor ECG, esp. if also combined w/ CYP2C8, CYP3A4 inhibitors, or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (gut P-gp-mediated transport inhibited)

Caution Advised

• aclidinium inhaled
Imodium A-D (loperamide)

+

aclidinium inhaled

1 interaction

Caution Advised

loperamide + aclidinium inhaled

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• alfentanil
Imodium A-D (loperamide)

+

alfentanil

1 interaction

Caution Advised

loperamide + alfentanil

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• alosetron
Imodium A-D (loperamide)

+

alosetron

1 interaction

Caution Advised

loperamide + alosetron

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• amantadine
Imodium A-D (loperamide)

+

amantadine

1 interaction

Caution Advised

loperamide + amantadine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• amitriptyline
Imodium A-D (loperamide)

+

amitriptyline

1 interaction

Caution Advised

loperamide + amitriptyline

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• amoxapine
Imodium A-D (loperamide)

+

amoxapine

1 interaction

Caution Advised

loperamide + amoxapine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• atropine
Imodium A-D (loperamide)

+

atropine

1 interaction

Caution Advised

loperamide + atropine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• barium
Imodium A-D (loperamide)

+

barium

1 interaction

Caution Advised

loperamide + barium

caution advised: combo may incr. risk of intestinal obstruction (additive effects)

• belladonna alkaloids
Imodium A-D (loperamide)

+

belladonna alkaloids

1 interaction

Caution Advised

loperamide + belladonna alkaloids

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• benztropine
Imodium A-D (loperamide)

+

benztropine

1 interaction

Caution Advised

loperamide + benztropine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• brompheniramine
Imodium A-D (loperamide)

+

brompheniramine

1 interaction

Caution Advised

loperamide + brompheniramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• buprenorphine
Imodium A-D (loperamide)

+

buprenorphine

1 interaction

Caution Advised

loperamide + buprenorphine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• butorphanol
Imodium A-D (loperamide)

+

butorphanol

1 interaction

Caution Advised

loperamide + butorphanol

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• carbinoxamine
Imodium A-D (loperamide)

+

carbinoxamine

1 interaction

Caution Advised

loperamide + carbinoxamine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• chlophedianol
Imodium A-D (loperamide)

+

chlophedianol

1 interaction

Caution Advised

loperamide + chlophedianol

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• chlorpheniramine
Imodium A-D (loperamide)

+

chlorpheniramine

1 interaction

Caution Advised

loperamide + chlorpheniramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• chlorpromazine
Imodium A-D (loperamide)

+

chlorpromazine

1 interaction

Caution Advised

loperamide + chlorpromazine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• clemastine
Imodium A-D (loperamide)

+

clemastine

1 interaction

Caution Advised

loperamide + clemastine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• clidinium
Imodium A-D (loperamide)

+

clidinium

1 interaction

Caution Advised

loperamide + clidinium

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• codeine
Imodium A-D (loperamide)

+

codeine

1 interaction

Caution Advised

loperamide + codeine

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• cyclobenzaprine
Imodium A-D (loperamide)

+

cyclobenzaprine

1 interaction

Caution Advised

loperamide + cyclobenzaprine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• cyproheptadine
Imodium A-D (loperamide)

+

cyproheptadine

1 interaction

Caution Advised

loperamide + cyproheptadine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• darifenacin
Imodium A-D (loperamide)

+

darifenacin

1 interaction

Caution Advised

loperamide + darifenacin

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• dexbrompheniramine
Imodium A-D (loperamide)

+

dexbrompheniramine

1 interaction

Caution Advised

loperamide + dexbrompheniramine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• dexchlorpheniramine
Imodium A-D (loperamide)

+

dexchlorpheniramine

1 interaction

Caution Advised

loperamide + dexchlorpheniramine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• dicyclomine
Imodium A-D (loperamide)

+

dicyclomine

1 interaction

Caution Advised

loperamide + dicyclomine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• difenoxin
Imodium A-D (loperamide)

+

difenoxin

1 interaction

Caution Advised

loperamide + difenoxin

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• dihydrocodeine
Imodium A-D (loperamide)

+

dihydrocodeine

1 interaction

Caution Advised

loperamide + dihydrocodeine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• dimenhydrinate
Imodium A-D (loperamide)

+

dimenhydrinate

1 interaction

Caution Advised

loperamide + dimenhydrinate

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• diphenhydramine
Imodium A-D (loperamide)

+

diphenhydramine

1 interaction

Caution Advised

loperamide + diphenhydramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• diphenoxylate
Imodium A-D (loperamide)

+

diphenoxylate

1 interaction

Caution Advised

loperamide + diphenoxylate

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• doxepin
Imodium A-D (loperamide)

+

doxepin

1 interaction

Caution Advised

loperamide + doxepin

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• doxepin topical
Imodium A-D (loperamide)

+

doxepin topical

1 interaction

Caution Advised

loperamide + doxepin topical

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• doxylamine
Imodium A-D (loperamide)

+

doxylamine

1 interaction

Caution Advised

loperamide + doxylamine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• erenumab
Imodium A-D (loperamide)

+

erenumab

1 interaction

Caution Advised

loperamide + erenumab

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• fentanyl
Imodium A-D (loperamide)

+

fentanyl

1 interaction

Caution Advised

loperamide + fentanyl

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• fesoterodine
Imodium A-D (loperamide)

+

fesoterodine

1 interaction

Caution Advised

loperamide + fesoterodine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• flavoxate
Imodium A-D (loperamide)

+

flavoxate

1 interaction

Caution Advised

loperamide + flavoxate

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• fluphenazine
Imodium A-D (loperamide)

+

fluphenazine

1 interaction

Caution Advised

loperamide + fluphenazine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• glycopyrrolate
Imodium A-D (loperamide)

+

glycopyrrolate

1 interaction

Caution Advised

loperamide + glycopyrrolate

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• glycopyrrolate inhaled
Imodium A-D (loperamide)

+

glycopyrrolate inhaled

1 interaction

Caution Advised

loperamide + glycopyrrolate inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• glycopyrronium topical
Imodium A-D (loperamide)

+

glycopyrronium topical

1 interaction

Caution Advised

loperamide + glycopyrronium topical

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• homatropine
Imodium A-D (loperamide)

+

homatropine

1 interaction

Caution Advised

loperamide + homatropine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• hydrocodone
Imodium A-D (loperamide)

+

hydrocodone

1 interaction

Caution Advised

loperamide + hydrocodone

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• hydromorphone
Imodium A-D (loperamide)

+

hydromorphone

1 interaction

Caution Advised

loperamide + hydromorphone

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• imipramine
Imodium A-D (loperamide)

+

imipramine

1 interaction

Caution Advised

loperamide + imipramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• ipratropium inhaled
Imodium A-D (loperamide)

+

ipratropium inhaled

1 interaction

Caution Advised

loperamide + ipratropium inhaled

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• levorphanol
Imodium A-D (loperamide)

+

levorphanol

1 interaction

Caution Advised

loperamide + levorphanol

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• loxapine
Imodium A-D (loperamide)

+

loxapine

1 interaction

Caution Advised

loperamide + loxapine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• meclizine
Imodium A-D (loperamide)

+

meclizine

1 interaction

Caution Advised

loperamide + meclizine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• meperidine
Imodium A-D (loperamide)

+

meperidine

1 interaction

Caution Advised

loperamide + meperidine

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• methscopolamine
Imodium A-D (loperamide)

+

methscopolamine

1 interaction

Caution Advised

loperamide + methscopolamine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• metoclopramide
Imodium A-D (loperamide)

+

metoclopramide

1 interaction

Caution Advised

loperamide + metoclopramide

caution advised: combo may decr. efficacy of both drugs (antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying)

• mexiletine
Imodium A-D (loperamide)

+

mexiletine

1 interaction

Caution Advised

loperamide + mexiletine

caution advised: combo may decr. peak mexiletine levels, delay antiarrhythmic onset (absorption delayed)

• mirtazapine
Imodium A-D (loperamide)

+

mirtazapine

1 interaction

Caution Advised

loperamide + mirtazapine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• molindone
Imodium A-D (loperamide)

+

molindone

1 interaction

Caution Advised

loperamide + molindone

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• morphine
Imodium A-D (loperamide)

+

morphine

1 interaction

Caution Advised

loperamide + morphine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• nalbuphine
Imodium A-D (loperamide)

+

nalbuphine

1 interaction

Caution Advised

loperamide + nalbuphine

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• nortriptyline
Imodium A-D (loperamide)

+

nortriptyline

1 interaction

Caution Advised

loperamide + nortriptyline

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• olanzapine
Imodium A-D (loperamide)

+

olanzapine

1 interaction

Caution Advised

loperamide + olanzapine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (incl. life-threatening), other anticholinergic adverse effects (additive effects)

• orphenadrine
Imodium A-D (loperamide)

+

orphenadrine

1 interaction

Caution Advised

loperamide + orphenadrine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• oxybutynin
Imodium A-D (loperamide)

+

oxybutynin

1 interaction

Caution Advised

loperamide + oxybutynin

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• oxycodone
Imodium A-D (loperamide)

+

oxycodone

1 interaction

Caution Advised

loperamide + oxycodone

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• oxymorphone
Imodium A-D (loperamide)

+

oxymorphone

1 interaction

Caution Advised

loperamide + oxymorphone

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• pentazocine
Imodium A-D (loperamide)

+

pentazocine

1 interaction

Caution Advised

loperamide + pentazocine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• perphenazine
Imodium A-D (loperamide)

+

perphenazine

1 interaction

Caution Advised

loperamide + perphenazine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• pheniramine
Imodium A-D (loperamide)

+

pheniramine

1 interaction

Caution Advised

loperamide + pheniramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• potassium acid phosphate
Imodium A-D (loperamide)

+

potassium acid phosphate

1 interaction

Caution Advised

loperamide + potassium acid phosphate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium gluconate
Imodium A-D (loperamide)

+

potassium gluconate

1 interaction

Caution Advised

loperamide + potassium gluconate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• potassium phosphate
Imodium A-D (loperamide)

+

potassium phosphate

1 interaction

Caution Advised

loperamide + potassium phosphate

caution advised w/ solid potassium formulations; liquid potassium formulations OK: combo may incr. risk of GI ulcerative, stenotic lesions (GI transit delayed, increased local exposure to high potassium concentration)

• prochlorperazine
Imodium A-D (loperamide)

+

prochlorperazine

1 interaction

Caution Advised

loperamide + prochlorperazine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• promethazine
Imodium A-D (loperamide)

+

promethazine

1 interaction

Caution Advised

loperamide + promethazine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• protriptyline
Imodium A-D (loperamide)

+

protriptyline

1 interaction

Caution Advised

loperamide + protriptyline

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• pyrilamine
Imodium A-D (loperamide)

+

pyrilamine

1 interaction

Caution Advised

loperamide + pyrilamine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• quetiapine
Imodium A-D (loperamide)

+

quetiapine

1 interaction

Caution Advised

loperamide + quetiapine

caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

• remifentanil
Imodium A-D (loperamide)

+

remifentanil

1 interaction

Caution Advised

loperamide + remifentanil

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• scopolamine
Imodium A-D (loperamide)

+

scopolamine

1 interaction

Caution Advised

loperamide + scopolamine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• sofpironium topical
Imodium A-D (loperamide)

+

sofpironium topical

1 interaction

Caution Advised

loperamide + sofpironium topical

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• solifenacin
Imodium A-D (loperamide)

+

solifenacin

1 interaction

Caution Advised

loperamide + solifenacin

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• sufentanil
Imodium A-D (loperamide)

+

sufentanil

1 interaction

Caution Advised

loperamide + sufentanil

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• tapentadol
Imodium A-D (loperamide)

+

tapentadol

1 interaction

Caution Advised

loperamide + tapentadol

caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

• thiothixene
Imodium A-D (loperamide)

+

thiothixene

1 interaction

Caution Advised

loperamide + thiothixene

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• tolterodine
Imodium A-D (loperamide)

+

tolterodine

1 interaction

Caution Advised

loperamide + tolterodine

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• trifluoperazine
Imodium A-D (loperamide)

+

trifluoperazine

1 interaction

Caution Advised

loperamide + trifluoperazine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• trihexyphenidyl
Imodium A-D (loperamide)

+

trihexyphenidyl

1 interaction

Caution Advised

loperamide + trihexyphenidyl

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

• trimipramine
Imodium A-D (loperamide)

+

trimipramine

1 interaction

Caution Advised

loperamide + trimipramine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• triprolidine
Imodium A-D (loperamide)

+

triprolidine

1 interaction

Caution Advised

loperamide + triprolidine

caution advised: combo may incr. risk of severe constipation/paralytic ileus (additive effects)

• trospium
Imodium A-D (loperamide)

+

trospium

1 interaction

Caution Advised

loperamide + trospium

caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)